US incentive scheme for neglected diseases: a good idea gone wrong?
Description
The US priority review voucher scheme was intended to encourage drug companies to invest in treatments for neglected diseases. But nearly seven years on, the author reports, there is little demonstrated innovation and evidence that the benefits are not going where they were intended.Citation
Doshi, P. (2014). US incentive scheme for neglected diseases: a good idea gone wrong? BMJ, 349. DOI: 10.1136/bmj.g4665Keyword
Knight Therapeuticsmiltefosine
priority review vouchers
Drug Approval--economics
Neglected Diseases--drug therapy
United States. Food and Drug Administration
Identifier to cite or link to this item
http://hdl.handle.net/10713/6607ae974a485f413a2113503eed53cd6c53
10.1136/bmj.g4665